www.dailypolitical.com ·
Pasithea Therapeutics Nasdaqktta Issues Quarterly Earnings Results
Topic context
This topic has been covered 298571 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedPasithea Therapeutics is a biotech company. The earnings beat is a company-specific event with no disclosed commercial mechanism (no product revenue, pipeline update, or partnership). The impact is limited to the company's stock price and investor sentiment. No sector-wide or supply-chain implications.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Pasithea Therapeutics (NASDAQ:KTTA) reported EPS of ($0.12), beating consensus estimate of ($0.45) by $0.33.
- Stock traded at $0.78 with volume of 549,445 shares on May 15, 2026.
- Market capitalization is $19.46 million.
- Institutional investors own 23.92% of the stock.
- Analysts have mixed ratings: one 'Buy', two 'Sell', consensus price target $3.00.
Related stories
fool.com
Keysight Keys Q2 2026 Earnings Transcript
livemint.com
Haryana Bars Petrol Diesel Cabs for Aggregators What Means Pm Modis Austerity Push Ncrs Aqi Fuel News
proactiveinvestors.com.au
The Morning Catch Up Asx Set to Open Lower Ahead of Pivotal Nvidia Earnings
nbclosangeles.com
Spacex Confirms Plans for IPO
finance.yahoo.com